PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Mark Schnute to Speak at Protein Kinases Drug Design October 24-25 in San Diego - Mark Schnute, Associate Research Fellow at Pfizer To Give a Presentation at the 2nd Protein Kinases & Drug Design Conference - GTCbio.com
Mark Schnute to Speak at Protein Kinases Drug Design October 24-25 in San Diego

 

NewswireToday - /newswire/ - Monrovia, CA, United States, 2013/09/05 - Mark Schnute, Associate Research Fellow at Pfizer To Give a Presentation at the 2nd Protein Kinases & Drug Design Conference - GTCbio.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Mark Schnute, Associate Research Fellow at Pfizer will give a presentation on “Targeted Covalent-Reversible Inhibitors of Bruton’s Tyrosine Kinase for the Treatment of Autoimmune Disease” at the 2nd Protein Kinases & Drug Design Conference to be held in San Diego, CA on October 24-25, 2013 by GTC.

Targeting of non-catalytic cysteine residues with covalent inhibitors is a powerful strategy for optimizing pharmacologic potency and selectivity on challenging targets such as protein kinases. Nonetheless, concerns over off-target modification of proteins by irreversible covalent inhibitors leading to idiosyncratic toxicity has led to caution in applying this strategy to chronic diseases such as inflammation and autoimmune indication even though these events are rare. The utilization of covalent inhibitors that reversibly form an adduct with the protein cysteine is attractive as they may provide the pharmacodynamic and selectivity benefit with less propensity to form long-lived protein adducts.

Dr. Schnute’s this presentation will describe a strategy to design, optimize and characterize covalent, reversible inhibitors targeting Bruton’s Tyrosine Kinase (Btk) and demonstrate their potential utility towards the treatment of inflammatory and autoimmune diseases. Structure-based drug design was utilized to optimize non-covalent inhibitor contacts within the kinase and guide placement of the covalent reactive group. Subsequent tuning of the reactivity and specificity of the electrophile resulted in the discovery of a class of highly selective Btk inhibitors within the cysteine homolog family. Through this strategy, it was identified that an orally bioavailable, potent and selective small molecule inhibitor of Btk which forms a covalent but reversible adduct with the enzyme as confirmed through enzymology, co-crystal structure analysis and mass spectroscopic characterization. The Btk inhibitor has been shown to be efficacious in several preclinical animal models of arthritis and autoimmune disease. This compound represents a new class of covalent Btk inhibitors which offers promise as a clinical candidate for the treatment of autoimmune and inflammatory diseases.

Kinases, key drivers of malignant transformation and major contributors to a variety of other human pathologies, have emerged as some of the most exciting targets in drug discovery. However, with initial well documented success stories came realization that many hurdles lie in the path of successful development of new drugs, targeting kinase signaling. GTC’s 2nd Protein Kinases & Drug Design Conference (gtcbio.com) will bring together speakers representing world leading academic centers and pharmaceutical companies to discuss how to overcome the many hurdles and answer exciting key questions.

This conference is part of our Protein Discovery Summit 2013, which includes three additional parallel conferences shown below:

• Protein Kinases & Drug Design;
• Protein-Protein Interaction;
• Antibody & Protein Therapeutics;
• Protein Expression, Purification & Characterization.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Mark Schnute to Speak at Protein Kinases Drug Design October 24-25 in San Diego

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: GTCbio.com 
626-256-6405 infogtcbio[.]gtcbio.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GTCbio - Biopharmaceutical Conference securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From GTCbio - Biopharmaceutical Conference / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Veritor™ System Meets FDA’s New Performance Requirements for Rapid Influenza Antigen Detection Tests
Sub-Sahara Africa - Increase in Western Lifestyles Leads to Dire Need for Chronic Prescription Drugs Finds Frost & Sullivan
BD Initiates New Industry Alliance to Combat Rising Opioid Crisis
BTG and Society of Interventional Oncology to Explore Role of Minimally Invasive Therapies in Immuno-oncology
Ipsen to Acquire a Portfolio of Select Consumer Healthcare Products from Sanofi
BD Announces Early Access Program for BD Resolve™ Single-Cell Analysis Platform
Precision Medicine Unlocks the Future of Targeted Therapy in the Global Healthcare Industry Finds Frost & Sullivan
Sciformix Corporation Receives Prestigious 2017 Global Outsourcing Customer Service Leadership Award from Frost & Sullivan
Arven Pharmaceuticals Selects GE Healthcare’s FlexFactory to Improve Turkish and Regional Access to Biopharmaceuticals
Ipsen to Acquire Primary Care Platform in Italy from Akkadeas Pharma
Cost-Containment and Client-Centric Services Catalyse European Custom Procedure Trays and Packs Market Finds Frost & Sullivan
New BD Institute for Medication Management Excellence Aims to Improve Patient Safety and Outcomes through Collaboration
New Varicose Vein Treatment Offers Minimally Invasive Non Surgical Procedure to Canadians
Greenphire and Exostar Partner to Deliver Seamless, Secure Access to Clinical Research Site Payment Solution
PleurX™ Catheter System Receives FDA 510(k) Clearance for Specific Non-Malignant Recurrent Pleural Effusions

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)